Serina Therapeutics Stock Price, News & Analysis
Company Description
Serina Therapeutics (NYSE: SER) is a publicly traded biotechnology company in the Pharmaceutical Preparations sector. The company has a market capitalization of $27.1M, ranking #6,119 among all listed U.S. companies by market cap.
SER stock has declined 68.5% over the past year. Shares last traded at $1.94.
On a trailing twelve-month basis, Serina Therapeutics reported revenue of $130K with net income of -$19.2M and diluted earnings per share of $-1.91. The company operates at a net profit margin of -14755.4%.
This page provides a comprehensive overview of SER stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Serina Therapeutics (SER) stock last traded at $1.94. Over the past 12 months, the stock has lost 68.5%. At a market capitalization of $27.1M, SER is classified as a micro-cap stock with approximately 15.0M shares outstanding.
SER Rankings
Latest News
Serina Therapeutics has 10 recent news articles. Of the recent coverage, 6 articles coincided with positive price movement and 4 with negative movement. Key topics include earnings, private placement, clinical trial, fda approval. View all SER news →
SEC Filings
Serina Therapeutics has filed 5 recent SEC filings, including 4 Form 4, 1 Form 8-K. The most recent filing was submitted on June 24, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all SER SEC filings →
Insider Radar
Insider buying activity at Serina Therapeutics over the past 90 days may reflect management confidence in the company's direction. Institutional investors and analysts often monitor insider purchases as a potential bullish indicator for the stock.
Financial Highlights
Serina Therapeutics generated $130K in revenue over the trailing twelve months, operating income reached -$24.0M (-18478.5% operating margin), and net income was -$19.2M, reflecting a -14755.4% net profit margin. Diluted earnings per share stood at $-1.91. The company generated -$18.0M in operating cash flow. With a current ratio of 1.71, the balance sheet reflects a strong liquidity position.
Upcoming Events
Cohort 1 completion
SMC review for Cohort 1
SAD TFL data release
Topline SAD results
Listing compliance cure deadline
Deadline to regain NYSE compliance
Serina Therapeutics has 6 upcoming scheduled events. Investors can track these dates to stay informed about potential catalysts that may affect the SER stock price.
Short Interest History
Short interest in Serina Therapeutics (SER) currently stands at 384.0 thousand shares, up 11.3% from the previous reporting period, representing 18.2% of the float. Over the past 12 months, short interest has increased by 1086.7%. This moderate level of short interest indicates notable bearish positioning.
Days to Cover History
Days to cover for Serina Therapeutics (SER) currently stands at 2.1 days, down 44% from the previous period. This days-to-cover ratio represents a balanced liquidity scenario for short positions. The ratio has shown significant volatility over the period, ranging from 1.0 to 4.1 days.
SER Company Profile & Sector Positioning
Serina Therapeutics (SER) operates in the Biotechnology industry within the broader Pharmaceutical Preparations sector and is listed on the NYSE.
Investors comparing SER often look at related companies in the same sector, including Vtv Therapeutics (VTVT), Polypid Ltd. (PYPD), JUPITER NEUROSCIENCES, INC. (JUNS), Relmada Therapeutics Inc (RLMD), and MAIA Biotechnology Inc. (MAIA). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate SER's relative position within its industry.